Advertisement
Canada markets open in 8 hours 2 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7306
    +0.0008 (+0.11%)
     
  • CRUDE OIL

    82.95
    +0.14 (+0.17%)
     
  • Bitcoin CAD

    87,672.05
    -3,819.47 (-4.17%)
     
  • CMC Crypto 200

    1,387.72
    -36.38 (-2.55%)
     
  • GOLD FUTURES

    2,327.90
    -10.50 (-0.45%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,426.75
    -237.75 (-1.35%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,660.20
    -799.88 (-2.08%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Thermo Fisher (TMO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2022, Thermo Fisher Scientific (TMO) reported revenue of $11.45 billion, up 7% over the same period last year. EPS came in at $5.40, compared to $6.54 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $10.36 billion, representing a surprise of +10.55%. The company delivered an EPS surprise of +4.05%, with the consensus EPS estimate being $5.19.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Organic Growth: -3% versus the four-analyst average estimate of -11.2%.

  • Revenues-Life Sciences Solutions: $3.05 billion versus the six-analyst average estimate of $2.76 billion. The reported number represents a year-over-year change of -26.6%.

  • Revenue-Analytical Instruments: $1.88 billion versus $1.66 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.

  • Revenue-Eliminations: -$536 million versus -$717.17 million estimated by six analysts on average.

  • Revenue-Laboratory Products and Biopharma Services: $5.95 billion compared to the $5.55 billion average estimate based on six analysts. The reported number represents a change of +41.8% year over year.

  • Revenue-Specialty Diagnostics: $1.12 billion versus $1.09 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -22.9% change.

  • Operating income-Life Sciences Solutions: $1.04 billion compared to the $1.12 billion average estimate based on three analysts.

  • Operating income-Laboratory Products and Biopharma Services: $836 million versus $694.79 million estimated by three analysts on average.

  • Operating Income-Specialty Diagnostics: $208 million versus the three-analyst average estimate of $220.02 million.

  • Operating income-Analytical Instruments: $476 million compared to the $397.11 million average estimate based on three analysts.

View all Key Company Metrics for Thermo Fisher here>>>

Shares of Thermo Fisher have returned +3.1% over the past month versus the Zacks S&P 500 composite's +6.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research